WBB Securities Initiates a Sell Rating on Motif Bio plc

By Carrie Williams

In a report released yesterday, Stephen Brozak from WBB Securities initiated coverage with a Sell rating on Motif Bio plc (NASDAQ: MTFB) and a price target of $7. The company’s shares opened today at $10.81.

Brozak said:

“We believe there is a critical need for novel antibiotics. Based on the clinical data provided through Phase 3 studies REVIVE-1 and REVIVE-2, iclaprim has a high probability of obtaining FDA approval. However, success for MTFB is not just manifest through clinical proof, but also through negotiating the vagaries of reimbursement, gaining clinician acceptance, hospital inclusion and inclusion in the overall patient care paradigm. Additionally, we remain concerned about the resourcing path regarding the future of iclaprim. We are therefore initiating our coverage of MTFB with a Sell rating and a 12- month price target of $7.00.”

According to TipRanks.com, Brozak is a 4-star analyst with an average return of 17.6% and a 54.5% success rate. Brozak covers the Healthcare sector, focusing on stocks such as Melinta Therapeutics Inc, Cascadian Therapeutics, and Sarepta Therapeutics.

Motif Bio plc has an analyst consensus of Hold, with a price target consensus of $19.50.

The company has a one-year high of $13.75 and a one-year low of $5.36. Currently, Motif Bio plc has an average volume of 5,438.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Motif Bio Plc is a clinical stage biopharmaceutical company which develops novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It pipeline of antibiotics includes iclaprim, and MTF-001, a preclinical program to design a dihydrofolate reductase inhibitor (DHFRi).